One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels

Michael C. Yau1,2, Robin Y. Kim1, Caroline K. Wang1, Jingru Li1, Tarek Ammar1, Runying Y. Yang1, Stephan A. Pless2, and Harley T. Kurata1

Retigabine is an antiepileptic drug and the first voltage-gated potassium (Kv) channel opener to be approved for human therapeutic use. Retigabine is thought to interact with a conserved Trp side chain in the pore of KCNQ2–5 (Kv7.2–7.5) channels, causing a pronounced hyperpolarizing shift in the voltage dependence of activation. In this study, we investigate the functional stoichiometry of retigabine actions by manipulating the number of retigabine-sensitive subunits in concatenated KCNQ3 channel tetramers. We demonstrate that intermediate retigabine concentrations cause channels to exhibit biphasic conductance–voltage relationships rather than progressive concentration-dependent shifts. This suggests that retigabine can exert its effects in a nearly “all-or-none” manner, such that channels exhibit either fully shifted or unshifted behavior. Supporting this notion, concatenated channels containing only a single retigabine-sensitive subunit exhibit a nearly maximal retigabine effect. Also, rapid solution exchange experiments reveal delayed kinetics during channel closure, as retigabine dissociates from channels with multiple drug-sensitive subunits. Collectively, these data suggest that a single retigabine-sensitive subunit can generate a large shift of the KCNQ3 conductance–voltage relationship. In a companion study (Wang et al. 2018. J. Gen. Physiol. https://doi.org/10.1085/jgp.201812014), we contrast these findings with the stoichiometry of a voltage sensor-targeted KCNQ channel opener (ICA-069673), which requires four drug-sensitive subunits for maximal effect.

Introduction

Voltage-gated potassium channels encoded by the KCNQ gene family are subject to dual regulation by voltage and PIP2 (Haley et al., 1998; Wang et al., 1998; Brown et al., 2007). In the central nervous system and certain sensory organs, KCNQ2–5 subunits encode the M-current, initially characterized as a hyperpolarizing potassium current sensitive to muscarinic signaling (Brown and Adams, 1980; Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998). Functional activity of KCNQ channels depends on the presence of adequate PIP2 levels in the membrane (Suh et al., 2006; Suh and Hille, 2007). Activation of signaling cascades that deplete PIP2, via M1-receptor activation or other G-protein–coupled receptors that signal through Gq and phospholipase C, lead to current reduction and consequently enhanced neuronal excitability (Brown and Passmore, 2009). KCNQ channels are also unique among the voltage-gated potassium channel family in that they are sensitive to a chemically diverse set of compounds that act as channel openers (Rentzen et al., 2006; Xiong et al., 2007, 2008; Miceli et al., 2008; Yu et al., 2011). Although a variety of compounds have been shown to exhibit KCNQ channel–activating properties, retigabine and its close analogue, flupirtine (used as an analgesic in some European countries), remain the only KCNQ channel activators to receive approval for clinical use (Blackburn-Munro et al., 2005; Orhan et al., 2012). Retigabine has been used as an adjunct therapeutic in drug-resistant epilepsies, with additional interest and investigation into its effectiveness for treatment of tinnitus, pain, hypertension, and neurodegenerative disorders (Passmore et al., 2003; Li et al., 2013b; Wainger et al., 2014; Kalappa et al., 2015).

There is an abundance of literature describing preclinical investigation of retigabine in animal models of seizures but comparably little on the molecular mechanisms underlying its action on KCNQ channels (Gunthorpe et al., 2012; Large et al., 2012). Retigabine causes a dramatic hyperpolarizing shift of the voltage dependence of activation, leading to enhanced KCNQ channel activation around the typical neuronal resting membrane potential and thus reduction of cellular excitability (Wuttke et al., 2005; Lange et al., 2009; Zhou et al., 2013). Retigabine-sensitive KCNQ2–5 channels share a conserved Trp side chain in the pore-forming S5 helix, which is essential for retigabine actions, and even conservative mutations to other aromatic side chains abolish the retigabine-induced gating shift (Schenzer et al., 2005; Kim et al., 2015). In addition to this conserved Trp,
other side chains in the KCNQ pore have been shown to influence retigabine sensitivity but are not strictly required (Lange et al., 2009). A recent report from our group has suggested the chemical basis for retigabine interaction with this conserved Trp is a hydrogen bond formed between the drug and the indole N-H group (Kim et al., 2015). Retigabine interaction with the pore domain generates a shift in the voltage sensor equilibrium through a PIP2-mediated coupling between the pore and voltage-sensing domain (Telezhkin et al., 2013; Soldovieri et al., 2016; Kim et al., 2017). Many complexities remain unresolved in our understanding of KCNQ activators. Most striking is the growing recognition of a variety of chemical scaffolds with KCNQ-activating properties and the likelihood that multiple mechanisms of action and binding sites may be targeted by this drug family (Padilla et al., 2009; Wang et al., 2017; Miceli et al., 2018).

Although channels formed by KCNQ2–5 subunits likely comprise four retigabine-binding sites, it has not been established how retigabine occupancy is translated to channel opening. We have addressed this question by investigating the functional stoichiometry of retigabine actions by manipulating the number of available retigabine-sensitive subunits in concatenated KCNQ3 channels. We demonstrate that in the presence of intermediate retigabine concentrations, channels exhibit biphasic conductance–voltage relationships. This behavior suggests that retigabine can exert its effects in a nearly “all-or-none” manner, with channels exhibiting either fully shifted or unshifted behavior. Using concatenated channels containing defined numbers of retigabine-sensitive subunits, we demonstrate that a single retigabine-sensitive subunit is required for a nearly maximal retigabine effect. As described in a companion paper (see Wang et al. in this issue), this property of retigabine contrasts with the voltage sensor–targeted KCNQ channel opener ICA-069673, which requires four drug-sensitive subunits to exert its full effect.

Materials and methods
Molecular biology and Xenopus laevis oocyte injections
Monomeric KCNQ3[A315T] channel cDNA was propagated and manipulated using the pSRC5 vector (gift of Dr. M. Taglialatela, University of Naples, Italy, and Dr. T. Jentsch, Max-Delbrück-Centrum für Molekulare Medizin, Germany). In all experiments involving homomeric expression of KCNQ3 channels, the Ala315Thr mutation was introduced to enable efficient trafficking of homomeric KCNQ3 (throughout the text, we refer to KCNQ3[A315Thr] as KCNQ3*; Zaika et al., 2008). Concatemeric constructs of KCNQ3* were generated by first creating dimers of combinations of KCNQ3* and KCNQ3*[W265F] and subcloning copies of the cDNA sequence into the Nhel-Xhol or Xhol-EcoRV restriction sites of pcDNA3.1(−). PCR primer design omitted a stop codon from the leading subunit, while preserving a stop codon in the trailing subunit. Sequences of individual inserts were confirmed by Sanger sequencing before combining them by restriction digestion and ligation, leading to a dimer of the form: Nhel-COPY1(no stop)-Xhol-COPY2-STOP-EcoRV. A second set of dimers was constructed with one subunit in the Nhel-Xhol position (stop codon omitted) and a second subunit cloned in the Xhol-EcoRV position but with an engineered Nhel site. These second dimers had the form Nhel-COPY1(no stop)-Xhol-COPY2(no stop)-Nhel-EcoRV. Using an Nhel digestion and ligation to combine these dimers, we generated a variety of tetrameric channel combinations of the form Nhel-COPY1(no stop)-Xhol-COPY2(no stop)-Nhel-COPY3(no stop)-Xhol-COPY4(STOP)-EcoRV, in pcDNA3.1(−). No linker sequences were added between any of the protomers. Sequences across the junctions were as follows (bold indicates the restriction site and additional amino acids introduced): junction 1 and 3 (Nhel), 5′-AAT AAG CCC ATT

Two-electrode voltage clamp, solutions, and pharmacology
Voltage-clamped potassium currents were recorded in modified Ringer’s solution (116 mM NaCl, 2 mM KCl, 1 mM MgCl2, 0.5 mM CaCl2, and 5 mM HEPES, pH 7.4) using an OC-725C voltage clamp (Warner). Glass microelectrodes were backfilled with 3 M KCl and had resistances of 0.1–1 MΩ. Data were filtered at 5 kHz and digitized at 10 kHz using a Digidata 1440A ( Molecular Devices) controlled by pClamp 10 software (Molecular Devices). Retigabine was purchased from Toronto Research Chemicals, stored as a 100 mM stock in DMSO, and diluted to working concentrations each experimental day.

Patch-clamp recordings and fast solution exchange
For rapid solution exchange experiments with retigabine, we used transfected HEK 293 cells. HEK293 cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were grown in Falcon tissue culture–treated flasks, in an incubator at 5% CO2 and 37°C. Cells were plated onto 12-well plates and allowed to settle for 24–48 h before transfection. Cells were transiently transfected with 1 µg of DNA encoding the channel of interest and 500 ng of GFP using jetPRIME DNA transfection reagent (Polyplus). 24 h after transfection, cells were plated onto sterile coverslips for electrophysiology experiments
the following day. Solutions were delivered at room temperature by pressure-driven flow through a multibarreled solution delivery turret driven by the RSC-200 (Biological) rapid solution changer to enable solution jumps.

Whole-cell patch-clamp recordings were performed using extracellular solution consisting of 135 mM NaCl, 5 mM KCl, 2.8 mM Na acetate, 1 mM CaCl2(2H2O), 1 mM MgCl2(6H2O), and 10 mM HEPES, with pH adjusted to 7.4. Intracellular solution contained 135 mM KCl, 5 mM EGTA, and 10 mM HEPES, with pH adjusted to 7.3. Glass pipette tips were manufactured using soda lime glass (Fisher Scientific) and had tip resistances of 1–3 MΩ in standard experimental solutions. Series resistance compensation of 75–85% was used in all recordings, and uncompensated series resistance did not exceed 4 MΩ. Recordings were filtered at 5 kHz and sampled at 10 kHz using an Axopatch-200B Digidata 1440A controlled by pClamp 10 software.

Data analysis
Voltage dependence of channel activation was fitted with a two-component Boltzmann equation of the form \( \frac{G}{G_{\text{max}}} = \frac{a}{1 + e^{-(V-V_{1/2,a})/k_a}} + \frac{1-a}{1 + e^{-(V-V_{1/2,b})/k_b}}, \) where \( V_{1/2,a} \) and \( V_{1/2,b} \) are the voltages, where each component is half-maximal, and \( k_a \) and \( k_b \) are slope factors reflecting the voltage range over which an e-fold change in open probability (Po) of the respective component is observed. In saturating drug conditions, or in control conditions, only a single component was required for an adequate fit. Concentration responses were fit with the following equation: Normalized conductance = \( \frac{G(0 \text{ RTG}) + (1 - G(0 \text{ RTG}))/\text{EC}_{50}}{(1 + \text{EC}_{50}/[\text{RTG}])^n}, \) where \( G(0 \text{ RTG}) \) is the conductance in zero retigabine, \( \text{EC}_{50} \) is the retigabine concentration that causes a half-maximal increase of normalized conductance, and \( n \) is a Hill coefficient.

Online supplemental material
Fig. S1 replots data from Fig. 5 to illustrate different responses to intermediate retigabine concentrations the concatenated channel constructs. Fig. S1 also provides conductance–voltage relationships collected from individual oocytes injected with the WFFF tetramer.

Results
KCNQ3 as a model to investigate retigabine stoichiometry
KCNQ2–5 channels exhibit a pronounced hyperpolarizing shift of the voltage dependence of activation in the presence of saturating concentrations of retigabine. In addition to the pore domain–delimited binding site for retigabine, other reports have suggested an alternative binding site for certain KCNQ openers, such as ICA-069673, in the voltage-sensing domain (Padilla et al., 2009; Gao et al., 2010; Li et al., 2013a; Wang et al., 2017, 2018). This alternative site has prominent effects in KCNQ2, but is absent or only weakly effective in KCNQ3 channels. Thus, homomeric KCNQ3 is a good model to selectively investigate retigabine interactions and effects via the conserved pore site. Although reports vary slightly in terms of the magnitude of the retigabine-mediated gating shift, we routinely observe large shifts of ~60 mV (Fig. 1 A and B) in saturating concentrations of retigabine (100–300 µM) for KCNQ3* channels (shortand used throughout to refer to homomeric KCNQ3[A315T], see Materials and methods) expressed in X. laevis oocytes (Kim et al., 2015).

Biphasic conductance–voltage relationships at intermediate retigabine concentrations
In experiments measuring retigabine effects on KCNQ3*, we previously observed a shallow slope of the conductance–voltage relationship at intermediate retigabine concentrations when compared with control or saturating conditions (Kim et al., 2015). We investigated this phenomenon in more detail with closely spaced voltage steps and observed prominent “splitting” of the conductance–voltage relationship into two components. This is apparent in Fig. 1 A (3 µM retigabine), in which tail current magnitudes are closely spaced after prepulses to intermediate voltages, leading to a shallow slope (plateau) between ~80 mV and ~50 mV in the conductance–voltage relationship (Fig. 1 B).
The retigabine-mediated shift in voltage dependence does not significantly alter the reversal potential (Fig. 1B, inset). The biphasic conductance–voltage relationship is well fit with a sum of two Boltzmann functions (Table 1). There is a dose-dependent increase in the contribution of the shifted component of the conductance–voltage relationship, with the retigabine-shifted component becoming more prominent with increasing retigabine concentrations (Fig. 2A). Using the magnitude of the shifted component, we calculated an EC50 of 4.4 µM with a Hill coefficient close to 1 (Fig. 2B). There is a modest increase of the V1/2 of the shifted component from −93.3 ± 0.3 mV at 1 µM retigabine to −103.3 ± 0.8 mV at saturating concentrations (Table 1). In addition, the “unshifted” component was best fit with a V1/2 of −41.8 ± 0.7 mV in control conditions and progressed to more hyperpolarized voltages.

| RTG concentration (µM) | Shifted component, a | V1/2a (mV) | V1/2b (mV) | ka | kb | n |
|------------------------|----------------------|-----------|-----------|----|----|---|
| 0                      | —                    | —         | −41.8 ± 0.7 | —  | 7.6 ± 0.2 | 5 |
| 1                      | 0.12                 | −93.3 ± 0.7 | −46.0 ± 1.1 | 5.9 ± 0.4 | 9.2 ± 0.3 | 5 |
| 3                      | 0.32                 | −93.5 ± 0.3 | −48.3 ± 1.2 | 6.9 ± 0.1 | 9.9 ± 0.6 | 5 |
| 10                     | 0.72                 | −98.8 ± 0.7 | −62.0 ± 1.7 | 7.6 ± 0.2 | 11.4 ± 0.5 | 5 |
| 30                     | 1                    | −97.4 ± 2.4 | —         | 9.4 ± 1.3 | —  | 5 |
| 100                    | 1                    | −103.3 ± 0.8 | —         | 7.9 ± 0.7 | —  | 5 |
| 300                    | 1                    | −102.0 ± 1.5 | —         | 9.2 ± 0.8 | —  | 5 |

Conductance–voltage relationships were fit with the equation G/Gmax = a/(1 + e−(V−V1/2,a)/ka) + (1 − a)/(1 + e−(V−V1/2,b)/kb). Data presented are mean ± SEM.

The retigabine-induced biphasic conductance–voltage relationships suggest the possibility that retigabine acts roughly in an all-or-none manner, reminiscent of recently reported effects of γ-subunits of BK (KCNMA1) channels (Gonzalez-Perez et al., 2014, 2015). Although a variety of mechanisms might underlie a biphasic conductance at a given drug concentration, our observation that increased retigabine concentrations cause an increased magnitude of the shifted component suggests that most channels are distributed between an unshifted state and a fully shifted state. To a rough approximation, altered drug concentrations appear to govern the ratio of channels in shifted and unshifted modes, as opposed to a progressive concentration-dependent shift of the V1/2 to more hyperpolarized voltages.

As described for BK channel modulation by γ-subunits, numerous stoichiometric channel/modulator configurations can generate an apparent all-or-none effect (Gonzalez-Perez et al., 2014). Experiments with homomeric KCNQ3* do not definitively demonstrate the number of retigabine molecules required to induce the shifted gating mode in KCNQ3* and do not demonstrate whether varying numbers of retigabine-sensitive subunits within a channel generate differential gating shifts. To investigate the stoichiometry of retigabine effects, we generated concatenated KCNQ3 channel constructs with varying numbers of KCNQ3* versus Trp265Phe subunits (Schenzer et al., 2005; Wuttke et al., 2005). Throughout the study, W refers to a WT Trp265-containing subunit, and F refers to a Trp265Phe mutant subunit (e.g., WWTF contains two WT subunits, and two Trp265Phe subunits). We confirmed that our plasmids encoded expression of full-length tetramers using Western blots (Fig. 3A) and also confirmed that concatenated channels exhibited similar gating properties relative to homomeric KCNQ3* channels (Fig. 3B and C). We had difficulties using the KCNQ3 antibody on lysates from X. laevis oocytes because of a high background signal, so Western blots were generated from lysates from HEK293 cells transfected with the same pcDNA3.1(−) concatenated channel constructs that were used to generate miRNA for oocyte recordings (Fig. 3A). At high concentrations of loaded protein (leftmost well, Fig. 3A), KCNQ3* (monomeric) channels exhibited a weak signal at a high molecular weight that likely reflects some oligomerization (left lane), although it primarily migrated as a monomer. At lower KCNQ3* concentrations (right lane), this higher-molecular-weight band was not as prominent. The higher-molecular-weight band did not perfectly align with the KCNQ3 signal from concatenated channels. Previous studies of concatenated tetrameric KCNQ1 (Meisel et al., 2012) and KCNQ2 (Gourgy-Hacohen et al., 2014) also compared monomeric and tetrameric constructs using Western blots, although their concatenation strategy was different from ours. Overall, it is challenging to definitively demonstrate whether the higher order oligomers align perfectly with the concatemers. However, our findings and these studies demonstrate that concatemeric constructs generate high molecular weight translated protein, suggesting that premature termination of translation (or spurious initiation of translation within the channel sequence) is infrequent. In our case, we were also reassured that all concatemers ran at a similar molecular weight, confirming that construction of the concatenated channel plasmids was consistent. We also validated the basic function of all the concatemers by demonstrating similar gating kinetics and voltage dependence as KCNQ3* in control conditions (Fig. 3, B and C). Similar to previous reports in KCNQ1 and KCNQ2, the voltage-dependent gating properties of
the KCNQ3* concatemers closely resembled homomeric KCNQ3* channels (Meisel et al., 2012; Gourgy-Hacohen et al., 2014).

The KCNQ3* concatemers closely resembled homomeric KCNQ3* channels (Meisel et al., 2012; Gourgy-Hacohen et al., 2014).

A single retigabine-sensitive subunit results in a large retigabine effect

We further validated the tetrameric construct design by directly comparing the retigabine sensitivity of the WWWWW tetramer with homomeric KCNQ3* channels. Fit data over a range of retigabine concentrations (KCNQ3* from Fig. 2) is overlaid on WWWWW data in Fig. 4 A for direct comparison. Conductance–voltage relationships exhibited similar biphasic properties in response to retigabine. The properties of currents generated from the WWWWW tetramer are also similar to homomeric KCNQ3* channels, illustrated by exemplar traces in 3 µM retigabine that closely resemble our initial observations presented in Fig. 1A. In addition, the concentration response of the tetrameric channel was very similar to KCNQ3* homomeric channels (Fig. 5).

We also characterized the retigabine response of concatenated channels with increasing numbers of retigabine-sensitive subunits (Fig. 5, A–D). All tetramers remained very responsive to retigabine although small differences were apparent at intermediate concentrations. For example, the WFFF tetramer (one retigabine-sensitive subunit) consistently exhibited a slightly smaller response relative to the other channels. These differences may be more apparent by examining conductance–voltage curves for each concatamer at a single retigabine concentration (see Fig. 5I, A and B). In terms of the maximal retigabine response (maximum ΔV1/2), channels with one sensitive subunit (WFFF) exhibited a shifted V1/2 of −91.9 ± 0.7 mV, slightly smaller than the WWWWW tetramer (V1/2 = −103 ± 3 mV). Channels with intermediate numbers of retigabine-sensitive subunits exhibited intermediate effects, but it is apparent that much of the maximal retigabine effect can be accounted for by a single drug-sensitive subunit (see maximally shifted conductance–voltage relationships in Fig. 5F).

We compared retigabine sensitivity using the normalized conductance at −60 mV (Fig. 5E). The apparent affinity increased slightly in channels with greater numbers of retigabine-sensitive subunits (Fig. 5E), but the affinity did not vary as steeply with subunit composition as one would predict with a simple model of four independent binding sites (WWWWW EC50 = 4 µM; WFFF EC50 = 7.7 µM). This observation may imply a cooperative response to retigabine binding, although this will require further study and validation given some of the challenges associated with these experiments. For example, we have observed that retigabine effects on KCNQ3 channels expressed in X. laevis oocytes become larger with longer incubation in the presence of the drug, and although we have maintained exposure times constant, this is certainly a likely source of uncertainty and variability. We also noted we may have failed to detect the full gating shift of the WFFF and WWFF concatemers (this is hinted by the shallower slope factor k for WWWF and WFFF in saturating retigabine; Table 2), but it is not practical to apply higher concentrations of retigabine, because drug solubility becomes an issue. It is also noteworthy that all of the concatenated channels, including the “single-site” WFFF, could reproduce the biphasic conductance–voltage relationships observed in KCNQ3* homomeric channels or the WWWWW tetramer. Although the effect in WFFF does not appear to be quite as pronounced as WWWWW in the averaged data, examination of records from individual oocytes illustrates the biphasic conductance–voltage relationship more clearly (Fig. S1 C). These observations suggest that a single functional retigabine site is sufficient to nearly completely shift the voltage dependence of channel gating. It was also interesting that the maximally shifted V1/2 measured in the WFFF tetramer (V1/2 = −91.9 ± 0.7 mV) is similar to the shifted V1/2 component measured at low retigabine concentrations (e.g., 3 µM) in either KCNQ3* channels (V1/2 = −93.5 ± 0.5 mV; Fig. 2A), or WWWWW tetramers (V1/2 = −93 ± 2 mV).
mV, Fig. 4 A). Although perhaps coincidental, this similar effect may suggest that the shifted component observed in low retigabine concentrations corresponds to a fraction of channels that are predominantly bound to a single retigabine molecule.

The retigabine-induced gating shift involves changes to both the activation (accelerated) and deactivation (decelerated) kinetics of KCNQ3. We compared the saturating effects of retigabine on channel gating kinetics in the series of KCNQ3* tetrameric channel constructs over a range of voltages (Fig. 6). Overall, activation kinetics are accelerated similarly whether channels have a full complement of four retigabine-sensitive subunits or just a single subunit (Fig. 6 B). Also, deactivation kinetics is decelerated by retigabine by a comparable extent whether there are one or four retigabine-sensitive subunits present (Fig. 6 C). These findings are consistent with the effects observed on the conductance–voltage relationship, suggesting that a single retigabine-sensitive subunit can account for most of the maximal retigabine effect.

Retigabine simultaneously occupies multiple drug-sensitive subunits

Although our findings demonstrate that a single drug-sensitive subunit can account for most of the effects of retigabine, these experiments do not distinguish whether multiple drug-sensitive subunits can be occupied simultaneously by retigabine. We directly tested this possibility using rapid solution exchange with HEK293 cells expressing either the WWWW or WFFF tetramers (Fig. 7). We held channels at various voltages after exposure to retigabine and then rapidly washed off the drug (exemplar sweeps at −20 mV and −60 mV are shown in Fig. 7). In the WFFF tetramer, retigabine wash off generates a monotonic reduction in current as the drug unbinds that is typically well described with a single time constant. This decay reflects a shift in the voltage dependence of activation as retigabine dissociates from the channels. In contrast, the WWWW tetramers exhibit a much more prominent delay of channel closure, leading to a clear sigmoidal reduction of current after rapid drug wash off (Fig. 7). This likely reflects dissociation of multiple drug molecules from the channel (while occupancy of a single subunit is sufficient to generate most of the shift in voltage-dependent gating), leading to a delayed current decay when multiple drug-sensitive subunits are present. Current decay in WWWW and WFFF tetramers was fit with a Hodgkin–Huxley–type equation of the form $I(t) = I(\infty) + (I(0) - I(\infty)) \times e^{-t/\tau}$, where $t = 0$ refers to the current immediately after retigabine wash off and $t = \infty$ refers to the steady-

Figure 3. Generation of KCNQ3* concatemers with variable stoichiometry of retigabine-sensitive subunits. (A) Western blots obtained from HEK293 cells expressing tetrameric constructs show predominant expression of tetrameric KCNQ3 protein, and the absence of monomeric subunits, in comparison to cells transfected with monomeric KCNQ3* control. (B and C) Representative activation and deactivation kinetics and summarized conductance–voltage relationships for all concatenated KCNQ3* channel constructs (W represents a native Trp at position 265, and F represents a Trp265Phe mutant subunit). No significant differences in $V_{1/2}$ or slope factor were detected in comparisons between the different concatenated channel types. Data points are mean ± SEM.

Figure 4. WWWW concatenated channels exhibit similar retigabine responses as homomeric KCNQ3*. (A) Conductance–voltage relationships were collected in multiple retigabine (RTG) concentrations using the same voltage protocol as Fig. 1. Overlaid blue curves are fits described in Fig. 2 and Table 1 for KCNQ3[A315T] channels (sum of two Boltzmann equations). Data are mean ± SEM. (B) Exemplar currents collected in 3 µM retigabine, illustrating the progression of tail currents that underlie the biphasic conductance–voltage relationship.
state current achieved after retigabine wash off. Current decay in WFFF tetramers was well fit with $n = 1$ or 2 ($\tau = 4,400 \pm 500$ ms at $-20$ mV and $4,600 \pm 500$ ms at $-60$ mV, $n = 6$). In contrast, current decay in WWWW tetramers was best fit with $n = 4$ ($\tau = 4,800 \pm 200$ ms at $-20$ mV and $4,600 \pm 200$ ms at $-60$ mV, $n = 5$). These findings support a general model that multiple subunits can bind to retigabine simultaneously, but drugs must unbind from all subunits to reverse the channel-activation effect.

**Mutations of other side chains in the putative retigabine-binding site cause a gating “supershift” with pronounced biphasic features**

Previous reports identified multiple amino acids in KCNQ2 or KCNQ3 channels that contribute to the putative retigabine-binding pocket in the pore domain (Fig. 8A). Mutations in this region, such as KCNQ3, L314, or L272, weaken retigabine sensitivity, but unlike Trp 265, they are not absolutely required for drug effects (Lange et al., 2009; Kim et al., 2015). With the recognition of the unique effects of retigabine on the KCNQ3* conductance–voltage relationship, we also examined the retigabine sensitivity of these binding pocket mutations in more detail. As previously reported, some of these mutations (L314A, L272I) cause a modest depolarizing shift of channel activation relative to KCNQ3* in control conditions but retain a similar $V_{1/2}$ in saturating retigabine concentrations. Thus the maximal retigabine-mediated gating shift in these mutants is even larger than in WT KCNQ3*, and the bipartisan nature of the conductance–voltage relationship is more pronounced (Fig. 8, C and D). Retigabine effects on these putative binding site mutants exhibits a similar progression of the magnitude of shifted and unshifted components, although higher retigabine concentrations are required than for KCNQ3* channels, reflecting the weaker retigabine sensitivity of these mutant channels (Fig. 8B). This exaggerated bipartisan nature of the conductance–voltage relationship (i.e., the absence of multiple intermediate components) adds confidence to our finding that intermediate retigabine concentrations cause channels to distribute primarily between nonshifted and fully shifted modes.

**Discussion**

Retigabine interaction with KCNQ2–5 potassium channels significantly alters the voltage dependence of channel activation (Schenzer et al., 2005; Wuttke et al., 2005). In the presence of saturating concentrations of retigabine, the hyperpolarizing shift of voltage dependence of these channels causes a greater

| Construct | Control $V_{1/2}$ (mV) | Max shifted $V_{1/2}$ (mV) | Control $k$ (mV) | Max shifted $k$ (mV) | $n$ |
|-----------|-------------------------|-----------------------------|------------------|----------------------|----|
| WWWW      | -44 ± 3                 | -103 ± 3                    | 9.4 ± 1.1        | 7.8 ± 0.4            | 5  |
| WWWF      | -43.8 ± 0.7             | -101.0 ± 1.3                | 6.9 ± 0.1        | 9.2 ± 0.1            | 5  |
| WWFF      | -44.1 ± 0.7             | -93 ± 1                     | 6.9 ± 0.1        | 12.0 ± 0.6           | 5  |
| WFFF      | -43.4 ± 1.2             | -91.9 ± 0.7                 | 9.3 ± 0.5        | 11.1 ± 0.2           | 5  |
| FFFF      | -42.8 ± 0.9             | -46.3 ± 1                   | 8.4 ± 0.9        | 7.3 ± 0.7            | 5  |

Conductance–voltage relationships were fit with the equation $G/G_{\max} = 1/(1 + e^{-(V-V_{1/2})/k})$. Data are mean ± SEM.

**Figure 5. A single retigabine-sensitive subunit encodes a large retigabine effect. (A–D)** Summary conductance–voltage relationships from WWWF (A), WWFF (B), WFFF (C), and FFFF (D) concatenated constructs, expressed in X. laevis oocytes and incubated in various retigabine (RTG) concentrations. (E) Summary data of the concentration–response of retigabine-mediated channel activation at −60 mV. (F) Maximal RTG-induced shift in $V_{1/2}$ for different constructs. See also Table 2 (data for FFFF are not shown). Data are mean ± SEM.
fraction to remain open in the normal range of neuronal resting membrane potentials. This hyperpolarizing effect is thought to underlie the therapeutic benefit of retigabine in diseases of membrane excitability like epilepsy. Using homomeric KCNQ3* channels as a model system, we investigated the number of retigabine-sensitive subunits required for a maximal retigabine response. We generated concatenated tetrameric subunits and varied the number of channel subunits carrying the Trp265Phe mutation previously shown to abolish retigabine sensitivity (Schenzer et al., 2005; Wuttke et al., 2005). It should be noted that KCNQ3*[Trp265Phe] mutant channels exhibit no response to the highest experimentally achievable concentrations of retigabine and are presumed to abolish binding, although no direct investigation of retigabine binding to WT or mutant channels has been reported (Kim et al., 2015). Because of this uncertainty, we have chosen to refer to the number of retigabine-sensitive subunits rather than the number of retigabine-binding sites.

The presence of a single retigabine-sensitive subunit was sufficient to reproduce most of the maximal retigabine response observed in homomeric KCNQ3* channels as a model system, we investigated the number of retigabine-sensitive subunits required for a maximal retigabine response. We generated concatenated tetrameric subunits and varied the number of channel subunits carrying the Trp265Phe mutation previously shown to abolish retigabine sensitivity (Schenzer et al., 2005; Wuttke et al., 2005). It should be noted that KCNQ3*[Trp265Phe] mutant channels exhibit no response to the highest experimentally achievable concentrations of retigabine and are presumed to abolish binding, although no direct investigation of retigabine binding to WT or mutant channels has been reported (Kim et al., 2015). Because of this uncertainty, we have chosen to refer to the number of retigabine-sensitive subunits rather than the number of retigabine-binding sites.

The presence of a single retigabine-sensitive subunit was sufficient to reproduce most of the maximal retigabine response observed in homomeric KCNQ3* channels (Figs. 4 and 5). The kinetic effects of retigabine (acceleration of channel activation, deceleration of channel closure) were also consistent between the WFFF and WWWW concatenated channels. Collectively, these data suggest that a single retigabine-sensitive subunit is sufficient to generate nearly the full retigabine gating effect. This requirement for drug binding to a single subunit was also reflected in the kinetics of current decay observed after rapid wash off of retigabine. The presence of multiple drug-sensitive subunits results in a clear delay and sigmoidal time course of current decay, contrasting the monoexponential decay observed in WFFF tetramers. A consistent explanation for this observation is that the delay reflects unbinding of multiple retigabine molecules, as loss of channel potentiation would not be expected until the drug has unbound from all of the sensitive subunits. Monoexponential decay of the WFFF currents would then reflect reti-
Gabine unbinding from a single site (Fig. 7). Importantly, there are sometimes shortcomings or inconsistencies that arise when using a concatenation strategy that have been suggested to arise from unexpected assembly of subunits from different concatemers (McCormack et al., 1992; Sack et al., 2008). We have not been able to explicitly rule out assembly of higher-order oligomers of concatenated constructs in our study, but the observed differences in the retigabine sensitivity of different concatemers (Fig. 5), and particularly the kinetics of retigabine dissociation (Fig. 7), suggest the concatemers assemble as predicted.

An exaggerated biphasic response to retigabine could be engineered in supershifted channels carrying binding site mutations (Fig. 8). This observation is important, as it renders the biphasic nature of the conductance–voltage response much clearer (as opposed to a mixture of three or four Boltzmann components that might be less apparent in the data for homomeric KCNQ3* channels in Fig. 1). Interestingly, retigabine appears able to fully overcome the destabilization of channel opening caused by these binding site mutations rather than making a constant energetic contribution to intrinsic open state stability of the mutant channel. This may be important in disease-causing loss-of-function KCNQ2 or KCNQ3 mutations linked to epilepsies and whether retigabine might be an effective therapeutic in some of these cases. Second, the biphasic nature of voltage sensitivity in the presence of retigabine may influence how one considers dosing effects of the drug in clinical conditions. A drug causing a progressive hyperpolarizing shift of channel activation while maintaining a steep voltage sensitivity might be expected to have a steep concentration dependence over which the drug becomes effective at a given voltage. In contrast, a gradual shift in the fraction of shifted/“potentiated” channels at a given voltage might broaden the range over which the drug can have a biological effect. Although a retigabine-induced biphasic conductance–voltage relationship has not been previously reported for KCNQ2/3 channels, it has probably not been examined in detail and may be difficult to resolve, because (for reasons that remain unclear) KCNQ2/3 heteromers exhibit a smaller retigabine-induced ΔV1/2 than KCNQ2 or KCNQ3* homomeric channels (Kim et al., 2015).

Lastly, it is important to consider the mechanism underlying the biphasic nature of the conductance–voltage relationship in the presence of retigabine. In the case of γ-subunit regulation of BK channels, random assembly of BK channels with different numbers of auxiliary subunits is presumed to govern the division of channels into populations with distinct gating properties (Gonzalez-Perez et al., 2015). However, in the case of a small molecule, one might expect channel–drug interactions to be more...
transient or dynamic. In this particular experiment, the biphasic nature of the conductance–voltage relationship likely reflects the affinity of retigabine binding to closed/resting channel states during the interpulse interval. At low concentrations, only a fraction of channels will be bound to retigabine during the interpulse interval and will be able to open at relatively negative voltages. To clearly divide available channels into distinct populations, we presume that slow binding and unbinding kinetics of retigabine (relative to the time scale of the experimental voltage pulses) are important to generate this feature in the data.

In conclusion, this study demonstrates that interaction of the prototype pore-targeted KCNQ channel opener retigabine with a single retigabine-sensitive subunit is sufficient to generate a nearly maximal drug-induced gating shift. In a companion paper (Wang et al., 2018), this finding is compared with an alter class of KCNQ channel openers that appear to target a distinct site in the voltage sensor and require a full complement of four drug-sensitive subunits to generate a maximal drug effect.

Acknowledgments

This study was funded by Canadian Institutes of Health Research operating grant MOP 142482. C.K. Wang was supported by a Canadian Institutes of Health Research CGS-M graduate award. R.Y. Kim was supported by a Canadian Institutes of Health Research CGS-D graduate award. H.T. Kurata is supported by a Canadian Institutes of Health Research New Investigator Award and the Alberta Diabetes Institute. S.A. Pless was supported by a Lundbeck Foundation Fellowship (R139-2012-12390).

M. Yau, S. Pless, and H. Kurata designed the experiments. M. Yau, R. Kim, C. Wang, J. Li, T. Ammar, and R. Yang performed experiments and analyzed data. M. Yau, S. Pless, and H. Kurata wrote the manuscript. All authors provided edits and approved the final version of the manuscript.

The authors declare no competing financial interests.

Author contributions: M. Yau, S. Pless, and H. Kurata designed the experiments. M. Yau, R. Kim, C. Wang, J. Li, T. Ammar, and R. Yang performed experiments and analyzed data. M. Yau, S. Pless, and H. Kurata wrote the manuscript. All authors provided edits and approved the final version of the manuscript.

Kenton J. Swartz served as editor.

Submitted: 26 January 2018
Accepted: 6 August 2018

References

Bentzen, B.H., N. Schmitt, K. Calloe, W. Dalby Brown, M. Grunnet, and S.P. Olsen. 2006. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 51:1068–1077. https://doi.org/10.1016/j.neuropharm.2006.07.001
Biervert, C., B.C. Schroeder, C. Kubisch, S.F. Berkovic, P. Propping, T.J. Jentsch, and O.K. Steinle. 1998. A potassium channel mutation in neontal human epilepsy. Science. 279:403–406. https://doi.org/10.1126/science.279.5349.403
Blackburn-Munro, G., W. Dalby-Brown, N.R. Mirza, J.D. Mikkelsen, and R.E. Blackburn-Munro. 2005. Retigabine: synthetic chemical to clinical application. CNS Drug Rev. 11:1–20. https://doi.org/10.1101/jif.1527-3458.2005.tb00033.x
Brown, D.A., and P.R. Adams. 1980. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature. 283:673–676. https://doi.org/10.1038/283673a0
Brown, D.A., and G.M. Passmore. 2009. Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 156:1185–1195. https://doi.org/10.1111/j.1476-5381.2009.00111.x
Brown, D.A., S.A. Hughes, S.J. Marsh, and A. Tinker. 2007. Regulation of M(Kv7.2/7.3) channels in neurons byPIP2 and products of PIP2 hydrolysis: significance for receptor-mediated inhibition. J. Physiol. 582:917–925. https://doi.org/10.1111/j.1469-8137.2007.01498.x
Charl tier, C., N.A. Singh, S.G. Ryan, T.B. Lewis, B.E. Reus, R.J. Leach, and M. Leppert. 1998. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Genet. 18:53–55. https://doi.org/10.1038/ng0198-53
Gao, Z., T. Zhang, M. Wu, Q. Xiong, H. Sun, Y. Zhang, L. Zu, W. Wang, and M. Li. 2010. Isospecific prolongation of Kv7 (KCNQ) potassium channel opening mediated by two molecular determinants for drug-channel interactions. J. Biol. Chem. 285:28322–28332. https://doi.org/10.1074/jbc.M109.116392
Gonzalez-Perez, V., X.M. Xia, and C.J. Lingle. 2014. Functional regulation of BK potassium channels by y1 auxiliary subunits. Proc. Natl. Acad. Sci. USA. 111:4868–4873. https://doi.org/10.1073/pnas.1322123111
Gonzalez-Perez, V., X.M. Xia, and C.J. Lingle. 2015. Two classes of regulatory subunits coassemble in the same BK channel and independently regulate gating. Nat. Commun. 6:6341. https://doi.org/10.1038/ncomms10341
Gourgy-Hacohen, O., P. Kornilov, I. Pittel, A. Peretz, B. Attali, and Y. Paas. 2014. Capturing distinct KCNQ2 channel resting states by metal ion bridges in the voltage-sensor domain. J. Gen. Physiol. 144:513–527. https://doi.org/10.1085/jgp.20141221
Gunterhase, M.J., C.H. Large, and R. Sankar. 2012. The mechanism of action of retigabine (ezogabine), a first-in-class K+ opener channel for the treatment of epilepsy. Epilepsia. 53:412–424. https://doi.org/10.1111/j.1528-1167.2011.03365.x
Haley, J.E., F.C. Abogadie, P. Delmas, M. Dayrell, Y. Vallis, G. Milligan, M.P. Caulfield, D.A. Brown, and N.J. Buckley. 1998. The alpha subunit of Gq contributes to muscarinic inhibition of the M-type potassium current in sympathetic neurons. J. Neurosci. 18:4521–4531. https://doi.org/10.1523/JNEUROSCI.18-12-04521.1998
Kalappa, B.I., H. Soh, K.M. Duignan, T. Furuya, S. Edwards, A.V. Tzingounis, and T. Tsounopoulou. 2015. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus. J. Neurosci. 35:8829–8842. https://doi.org/10.1523/JNEUROSCI.5176-14.2015
Kim, R.Y., M.C. Yau, J.D. Galpin, G. Seehbohm, C.A. Ahern, S.A. Pless, and H.T. Kurata. 2015. Atomic basis for therapeutic activation of neuronal potassium channels. Nat. Commun. 6:8116. https://doi.org/10.1038/ncomms9116
Kim, R.Y., S.A. Pless, and H.T. Kurata. 2017. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels. Proc. Natl. Acad. Sci. USA. 114:E9702–E9711. https://doi.org/10.1073/pnas.1705802114
Lang e, W., J. Gissendörfer, A. Schenzer, J. Grötzinger, G. Seehbohm, T. Friedrich, and M. Schwake. 2009. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol. Pharmacol. 75:272–280. https://doi.org/10.1124/mol.108.052282
Large, C.H., D.M. Sokal, A. Nehlig, M.J. Guntherhase, R. Sankar, C.S. Crean, R.E. Vanlandingham, and H.S. White. 2012. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia. 53:425–436. https://doi.org/10.1111/j.1528-1167.2011.03364.x
Li, P., Z. Chen, H. Xu, H. Sun, H. Li, H. Liu, H. Yang, Z. Gao, H. Jiang, and M. Li. 2013a. The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands. Cell Res. 23:1106–1118. https://doi.org/10.1038/cr.2013.82
Li, S., V. Choi, and T. Tsounopoulou. 2013b. Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus. Proc. Natl. Acad. Sci. USA. 110:9980–9985. https://doi.org/10.1073/pnas.1302770110
McCormack, K., L. Lin, L.E. Iverson, M.A. Tanouye, and F.J. Sigworth. 1992. Transient linkage of Shaker K+ channel subunits does not ensure the stoichiometry of expressed channels. Biophys. J. 63:1406–1411. https://doi.org/10.1016/S0006-3495(92)81703-4
Meisel, E., M. Dvir, Y. Haitin, M. Giladi, A. Peretz, and B. Attali. 2012. KCNQ1 channels do not undergo concerted but sequential gating transitions in both the absence and the presence of KCNE1 protein. J. Biol. Chem. 287:34212–34224. https://doi.org/10.1074/jbc.M112.364901
Miceli, F., M.V. Soldovieri, M. Martire, and M. Tagliatalata. 2008. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr. Opin. Pharmacol. 8:65–74. https://doi.org/10.1016/j.coph.2007.10.003

Miceli, F., M.V. Soldovieri, P. Ambrosino, L. Manocchio, A. Medoro, I. Mosca, and M. Tagliatalata. 2018. Pharmacological Targeting Of Neuronal Kv7/2/3 Channels: A Focus On Chemotypes And Receptor Sites. Curr. Med. Chem. 25:2637–2660. https://doi.org/10.2174/092986732466617101212852

Orhan, G., T.V. Wurtke, A.T. Nies, M. Schwa, and H. Lerche. 2012. Retigabine/ Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin. Pharmacother. 13:1807–1816. https://doi.org/10.1517/14656566.2012.706278

Padilla, K., A.D. Wickenden, A.C. Gerlach, and K. McCormack. 2009. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci. Lett. 465:138–142. https://doi.org/10.1016/j.neulet.2009.08.071

Passmore, G.M., A.A. Selyanko, M. Mistry, M. Al-Qatari, S.J. Marsh, E.A. Matthews, A.H. Dickinson, T.A. Brown, S.A. Burbidge, M. Main, and D.A. Brown. 2003. KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. 23:7227–7236. https://doi.org/10.1523/JNEUROSCI.23-18-072272003

Sack, J.T., O. Shamotienko, and J.O. Dolly. 2008. How to validate a heteromeric ion channel drug target: assessing proper expression of concatenated subunits. J. Gen. Physiol. 131:415–420. https://doi.org/10.1085/jgp.200709939

Schenzer, A., T. Friedrich, M. Pusch, P. Saftig, T.J. Jentsch, J. Grötzinger, and M. Schwake. 2005. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J. Neurosci. 25:5051–5060. https://doi.org/10.1523/JNEUROSCI.0128-05.2005

Singh, N.A., C. Charlier, D. Stauffer, B.R. DuPont, R.J. Leach, R. Melis, G.M. Ronen, I. Bjerre, T. Quattlebaum, J.V. Murphy, et al. 1998. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. 18:25–29. https://doi.org/10.1038/ng0198-25

Soldovieri, M.V., P. Ambrosino, I. Mosca, M. De Maria, E. Moretto, F. Miceli, A. Alaimo, N. Iraci, L. Manocchio, A. Medoro, et al. 2016. Early-onset newborns. Nat. Genet. 18:25–29. https://doi.org/10.1038/ng0198-25

Wang, A.W., M.C. Yau, C.K. Wang, N. Sharmin, R.Y. Yang, S.A. Pless, and H.T. Kurata. 2008. Four drug-sensitive subunits are required for maximal effect of a voltage sensor-targeted KCNQ opener. J. Gen. Physiol. https://doi.org/10.1085/jgp.201812014

Wang, H.S., Z. Pan, W. Shi, B.S. Brown, R.S. Wymore, J.E. Dixon, and D. McKinnon. 1998. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 282:1890–1893. https://doi.org/10.1126/science.282.5395.1890

Wuttke, T.V., G. Seebohm, S. Bail, S. Maljevic, and H. Lerche. 2005. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 67:1009–1017. https://doi.org/10.1124/mol.104.010793

Xiong, Q., H. Sun, and M.L. Li. 2007. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat. Chem. Biol. 3:287–296. https://doi.org/10.1038/nchembio874

Xiong, Q., Z. Gao, W. Wang, and M. Li. 2008. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol. Sci. 29:99–107. https://doi.org/10.1016/j.tips.2007.11.010

Yau, H., M. Wu, S.D. Townsend, B. Zou, S. Long, J.S. Daniels, O.B. McManus, M. Li, C.W. Lindsay, and C.R. Hopkins. 2011. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem. Neurosci. 2:572–577. https://doi.org/10.1021/cn200065b

Zaika, O., C.C. Hernandez, M. Bal, G.P. Tolstykh, and M.S. Shapiro. 2008. Determinants within the turret and pore-loop domains of KCNQ3 K+ channels governing functional activity. Biophys. J. 95:5121–5137. https://doi.org/10.1529/biophysj.107.136704

Zhou, P., H. Yu, M. Gu, F.J. Nan, Z. Gao, and M. Li. 2013. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels. Proc. Natl. Acad. Sci. USA. 110:8726–8731. https://doi.org/10.1073/pnas.1302167110